… The very broad range of tyrosine kinase target mutations seen in ALK-rearranged lung cancer
with acquired resistance to crizotinib is reminiscent of the variety of resistance mutations to …

… This article appraises the key literature on the contemporary management of non-small cell
lung cancer patients with acquired resistance to EGFR TKIs, and envisions future directions …

… and focus on the major cause of mortality for lung cancer patients: acquired resistance. We
… acquired resistance, as it remains the major scientific and clinical challenge in lung cancer. …

… non–small cell lung cancer patients … resistance to these agents. Thus, there is a great need
to understand how patients become resistant to develop effective therapies for these cancers. …

… We did T790M testing on rebiopsy specimens from 93 patients with EGFR-mutant lung cancer
and acquired resistance to TKI and found that those with T790M-mediated resistance had …

… in classification of acquired resistance that require urgent … in lung cancer suggest unique
underlying determinants of durable clinical benefit and resistance in non-small-cell lung cancer (…

… About 5% of patients suffered from transformation from EGFR-mutant adenocarcinoma to
small-cell lung cancer (SCLC) after acquired resistance to EGFR TKIs [35]. A possible theory is …

… acquire resistance to either drug. Currently, the clinical definition of such secondary or
acquired resistance … be used to define more precisely acquired resistance to EGFR TKIs. All …

… Diversity and ductility in acquiring resistance to TKIs in EGFR-mutated lung cancers. HCC827
lung cancer cells, shown here, are frequently used as in vitro acquired resistance models; …

… resistance, which leads to development and progression of human epithelial cancers,
including non-small cell lung cancer (… However, acquired resistance to gefitinib and erlotinib via …